Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06200-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Manon Garcia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Service de Thérapie Cellulaire et d'Hématologie Clinique, CHU Estaing, Clermont-Ferrand, France. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The advent of BTK inhibitors has been transformative in the management of patients with chronic lymphocytic leukemia or other B-cell lymphoproliferative disorders. However, emergence of BTK or PLCG2 mutations lead to resistance to these compounds and are now a growing concern in clinical practice. Assessing BTK mutations is now becoming a priority to guide the therapeutic decision at further relapse. To this end, targeted next-generation sequencing (NGS) is a valid tool, but lack of sensitivity and the required time for delivering results remain major challenges. Digital PCR could be more sensitive but is also limited by the number of mutations that can be screened. We here overcame these challenges by multiplexing digital PCR (mdPCR) in three assays that can cover 96% of ibrutinib-resistant cases. We investigated a cohort of 28 patients progressing on ibrutinib and for whom NGS revealed BTK mutations (C481S, C481F and C481R) and/or PLCG2 R665W mutation. Overall, 49 mutations were detected by NGS and 68 by mdPCR. We found mdPCR to bemore sensitive than NGS, particularly at low allelic frequencies, making it more suitable for the detection and quantification of small mutated clones. Thus, mdPCR offers high sensitivity, is expected to be more rapid and cost-effective than NGS in detecting resistance mutations to improve the therapeutic choice at relapse after exposure to BTK inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Thérapie Cellulaire et d'Hématologie Clinique, CHU Estaing, Clermont-Ferrand, France.
- Université Clermont Auvergne, Unité de Recherche 7453 (CHELTER), Clermont-Ferrand, France.
- Laboratoire d'Hématologie, HUPSSD, Hôpital Avicenne, Bobigny, France.
- Université Sorbonne Paris Nord, INSERM U978, Bobigny, France.
- Service d'Hématologie Clinique, CHU de Reims, Reims, France.
- Université de Reims Champagne-Ardenne, IRMAIC, Reims, France.
Zitieren
APA
Garcia, M., Croizier, C., Lazarian, G., Quinquenel, A., Tassin, T., Bourgne, C., Tournilhac, O., Bay, J. O., Berger, M. G., Tchirkov, A., Véronèse, L., & Guièze, R. (2025). Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors. Annals of Hematology. https://doi.org/10.1007/s00277-025-06200-9
Vancouver
Garcia M, Croizier C, Lazarian G, Quinquenel A, Tassin T, Bourgne C, et al. Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors. Annals of Hematology. 2025. doi:10.1007/s00277-025-06200-9
BibTeX
@article{Garcia2025,
author = {Garcia, Manon and Croizier, Carolyne and Lazarian, Grégory and Quinquenel, Anne and Tassin, Thomas and Bourgne, Céline and Tournilhac, Olivier and Bay, Jacques-Olivier and Berger, Marc G and Tchirkov, Andréi and Véronèse, Lauren and Guièze, Romain},
title = {Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06200-9}
}
EUVIMED